Cargando…

Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients

Survival prognosis is challenging, and accurate prediction of individual survival times is often very difficult. Better statistical methodology and more data can help improve the prognostic models, but it is important that methods and data usages are evaluated properly. The Prostate Cancer DREAM Cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Wengel Mogensen, Søren, H. Petersen, Anne, Buchardt, Ann-Sophie, Hansen, Niels Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200946/
https://www.ncbi.nlm.nih.gov/pubmed/28105311
http://dx.doi.org/10.12688/f1000research.8427.1
_version_ 1782489271803838464
author Wengel Mogensen, Søren
H. Petersen, Anne
Buchardt, Ann-Sophie
Hansen, Niels Richard
author_facet Wengel Mogensen, Søren
H. Petersen, Anne
Buchardt, Ann-Sophie
Hansen, Niels Richard
author_sort Wengel Mogensen, Søren
collection PubMed
description Survival prognosis is challenging, and accurate prediction of individual survival times is often very difficult. Better statistical methodology and more data can help improve the prognostic models, but it is important that methods and data usages are evaluated properly. The Prostate Cancer DREAM Challenge offered a framework for training and blinded validation of prognostic models using a large and rich dataset on patients diagnosed with metastatic castrate resistant prostate cancer. Using the Prostate Cancer DREAM Challenge data we investigated and compared an array of methods combining imputation techniques of missing values for prognostic variables with tree-based and lasso-based variable selection and model fitting methods. The benchmark metric used was integrated AUC (iAUC), and all methods were benchmarked using cross-validation on the training data as well as via the blinded validation. We found that survival forests without prior variable selection achieved the best overall performance (cv-iAUC = 0.70, validation-iACU = 0.78), while a generalized additive model was best among those methods that used explicit prior variable selection (cv-iAUC = 0.69, validation-iACU = 0.76). Our findings largely concurred with previous results in terms of the choice of important prognostic variables, though we did not find the level of prostate specific antigen to have prognostic value given the other variables included in the data.
format Online
Article
Text
id pubmed-5200946
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-52009462017-01-18 Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients Wengel Mogensen, Søren H. Petersen, Anne Buchardt, Ann-Sophie Hansen, Niels Richard F1000Res Method Article Survival prognosis is challenging, and accurate prediction of individual survival times is often very difficult. Better statistical methodology and more data can help improve the prognostic models, but it is important that methods and data usages are evaluated properly. The Prostate Cancer DREAM Challenge offered a framework for training and blinded validation of prognostic models using a large and rich dataset on patients diagnosed with metastatic castrate resistant prostate cancer. Using the Prostate Cancer DREAM Challenge data we investigated and compared an array of methods combining imputation techniques of missing values for prognostic variables with tree-based and lasso-based variable selection and model fitting methods. The benchmark metric used was integrated AUC (iAUC), and all methods were benchmarked using cross-validation on the training data as well as via the blinded validation. We found that survival forests without prior variable selection achieved the best overall performance (cv-iAUC = 0.70, validation-iACU = 0.78), while a generalized additive model was best among those methods that used explicit prior variable selection (cv-iAUC = 0.69, validation-iACU = 0.76). Our findings largely concurred with previous results in terms of the choice of important prognostic variables, though we did not find the level of prostate specific antigen to have prognostic value given the other variables included in the data. F1000Research 2016-11-16 /pmc/articles/PMC5200946/ /pubmed/28105311 http://dx.doi.org/10.12688/f1000research.8427.1 Text en Copyright: © 2016 Wengel Mogensen S et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Method Article
Wengel Mogensen, Søren
H. Petersen, Anne
Buchardt, Ann-Sophie
Hansen, Niels Richard
Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
title Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
title_full Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
title_fullStr Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
title_full_unstemmed Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
title_short Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients
title_sort survival prognosis and variable selection: a case study for metastatic castrate resistant prostate cancer patients
topic Method Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200946/
https://www.ncbi.nlm.nih.gov/pubmed/28105311
http://dx.doi.org/10.12688/f1000research.8427.1
work_keys_str_mv AT wengelmogensensøren survivalprognosisandvariableselectionacasestudyformetastaticcastrateresistantprostatecancerpatients
AT hpetersenanne survivalprognosisandvariableselectionacasestudyformetastaticcastrateresistantprostatecancerpatients
AT buchardtannsophie survivalprognosisandvariableselectionacasestudyformetastaticcastrateresistantprostatecancerpatients
AT hansennielsrichard survivalprognosisandvariableselectionacasestudyformetastaticcastrateresistantprostatecancerpatients